rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    SRPT
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Sarepta Therapeutics stock hits 52-week low at 14.68 USD
      Nov 17Investing.comSRPT
      DraftKings downgraded, Sarepta upgraded: Wall Street's top analyst calls
      Nov 10Yahoo FinanceDKNGSRPT
      Sarepta Therapeutics Sees Transformational 2027 as Rare Disease Programs Advance
      Nov 9Yahoo FinanceSRPT
      Sarepta at Guggenheim conference: cash flow funds a broad pipeline
      Nov 9Investing.comSRPT
      Learn Why The Bull Case For Sarepta Therapeutics Stock Could Change Following Raised Revenue Guidance

      Sarepta Therapeutics reported Q3 2026 revenue of US$381.35 million with a narrower net loss, and later raised the low end of its 2026 total net product revenue guidance by US$50 million to a range of US$1.25 billion to US$1.3 billion. The higher outlook leans on a stabilizing ELEVIDYS gene therapy business and a resilient PMO franchise, even as year-to-date revenue trails the prior period and Q3 earnings fell short of analyst expectations. This article examines how Sarepta Therapeutics'...

      Nov 7Yahoo FinanceSRPT
      Sarepta (SRPT) Q3 2026 Earnings Call Transcript

      Motley Fool Press Release.

      Nov 6The Globe and MailSRPT
      Sarepta Therapeutics Inc (SRPT) Q3 2026 Earnings Call Highlights: Revenue Guidance Raised ...
      Nov 6Yahoo FinanceSRPT
      Baird cuts Sarepta Therapeutics stock price target on growth concerns
      Nov 6Investing.comSRPT
      Sarepta Therapeutics Q3 Earnings Call Highlights
      Nov 6Yahoo FinanceSRPT
      Sarepta Therapeutics (SRPT) Q3 Earnings Lag Estimates
      Nov 6Yahoo FinanceSRPT
      Sarepta misses on the bottom line, but raises lower end of 2026 revenue guidance
      Nov 5Seeking AlphaSRPT
      Compared to Estimates, Sarepta Therapeutics (SRPT) Q3 Earnings: A Look at Key Metrics
      Nov 5Yahoo FinanceSRPT
      Sarepta Therapeutics Q3 2026 Earnings Call Transcript
      Nov 5BenzingaSRPT
      Sarepta earnings beat by $0.02, revenue topped estimates
      Nov 5Investing.comSRPT
      Sarepta Therapeutics: Q3 Earnings Snapshot
      Nov 5Yahoo FinanceSRPT
      Sarepta Therapeutics (SRPT) Earnings Preview Puts Its Fair Value Back In Focus
      Oct 30Yahoo FinanceSRPT
      RBC Capital Sticks to Its Hold Rating for Sarepta Therapeutics (SRPT)

      Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

      Oct 30The Globe and MailSRPT
      Sarepta Therapeutics to Announce Third Quarter 2026 Financial Results
      Oct 22Yahoo FinanceSRPT
      H.C. Wainwright reiterates Sarepta stock Sell rating at $5 target
      Oct 19Investing.comSRPT
      Sarepta Therapeutics Faces New Growth Opportunity Emerging From SiRNA Programs, Wedbush Says
      Oct 16Yahoo FinanceSRPT
      Sarepta shares preclinical data on DM1 treatment candidate
      Oct 14Investing.comSRPT
      Bank of America Securities Reaffirms Their Sell Rating on Sarepta Therapeutics (SRPT)

      Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

      Oct 10The Globe and MailSRPT
      RBC Cuts Price Target on Sarepta Therapeutics to $17 From $19, Keeps Sector Perform, Speculative Risk
      Oct 8Yahoo FinanceSRPT
      Jim Cramer Explains His Hesitation Over Sarepta (SRPT) Therapeutics
      Oct 7Yahoo FinanceSRPT
      Wells Fargo Sticks to Their Buy Rating for Sarepta Therapeutics (SRPT)

      Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

      Oct 6The Globe and MailSRPT
      JF's Daily Diligence: Sarepta Therapeutics (SRPT) (NASDAQ:SRPT)
      Oct 6Seeking AlphaSRPT
      Sarepta presents Elevidys data in older Duchenne patients
      Sep 30Investing.comSRPT
      Why Sarepta Therapeutics (SRPT) Is Down 7.2% After AAVrh74 Patent Peace With REGENXBIO And UPenn

      In September 2026, REGENXBIO and the University of Pennsylvania settled their patent infringement litigation with Sarepta Therapeutics and Catalent over ELEVIDYS, with Sarepta agreeing to pay US$39.0 million and receiving broad freedom to operate on AAVrh74-based gene therapies under specified patents. The settlement not only closes costly legal disputes but also removes a significant patent overhang on ELEVIDYS and related AAVrh74 programs, potentially clarifying Sarepta’s long-term gene...

      Sep 26Yahoo FinanceRGNXSRPT
      Jefferies reiterates Sarepta Therapeutics stock rating on pipeline potential
      Sep 24Investing.comSRPT
      Sarepta to present gene therapy data at neuromuscular meeting
      Sep 24Investing.comSRPT
      Sarepta Sees ELEVIDYS Demand Stabilizing as FSHD, DM1 Readouts Near

      Sarepta Therapeutics (NASDAQ:SRPT) outlined plans to stabilize demand for its ELEVIDYS gene therapy while advancing RNA-based programs for facioscapulohumeral muscular dystrophy, or FSHD, and myotonic dystrophy type 1, or DM1, during a Morgan Stanley Global Healthcare Conference fireside chat. Chie

      Sep 15Yahoo FinanceSRPT
      Sarepta at Morgan Stanley conference: pipeline data and sales recovery
      Sep 14Investing.comSRPTMS
      Sarepta Therapeutics climbs 10%, rebounding from recent slide (SRPT:NASDAQ)
      Sep 9Seeking AlphaSRPT
      H.C. Wainwright reiterates Sarepta stock Sell rating at $5 target
      Sep 9Investing.comSRPT
      Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers
      Sep 8ReutersDYNSRPTNVS
      Jefferies reiterates Sarepta Therapeutics stock rating on trial data outlook
      Sep 8Investing.comSRPT
      A Rivals Clinical Stumble Sends Sarepta Therapeutics Stock Lower
      Sep 8BenzingaSRPT
      Mizuho reiterates Sarepta stock rating after Novartis trial miss
      Sep 8Investing.comSRPTNVS
      Why is Sarepta Therapeutics stock sliding today?
      Sep 8Investing.comSRPT
      Novartis drops 13% on trial failure, dragging Dyne and Sarepta (NVS:NYSE)

      Novartis stock sinks 13% after del-desiran phase 3 trial failed primary endpoints, sparking biotech selloff.

      Sep 8Seeking AlphaDYNSRPTNVS
      Why Is Sarepta Therapeutics (SRPT) Up 37% Since Last Earnings Report?

      Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

      Sep 4Yahoo FinanceSRPT
      Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT
      Sep 4MorningstarSRPT
      Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

      CAMBRIDGE, Mass., August 31, 2026--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, Sept. 14, at 8:30 a.m. ET.

      Aug 31Yahoo FinanceSRPTMS
      Sarepta Stock: A Prove-It Story Now Defined By ELEVIDYS Execution (NASDAQ:SRPT)

      Sarepta (SRPT) is rated hold: ELEVIDYS uptake faces friction and execution risk despite better profitability. Read here for a detailed investment analysis.

      Aug 28Seeking AlphaSRPT
      SRPT On Track For Best Week In 5 Months Ahead Of Late-2026 Clinical Data — Retail Eyes ‘Monumental Comeback’

      Investors are now awaiting extra data from Sarepta’s mid-stage studies in two muscle diseases, facioscapulohumeral muscular dystrophy and myotonic dystrophy.

      Aug 27Yahoo FinanceSRPT
      Sarepta (SRPT) Stock Looks Fully Valued As Sales Trail Fair Value

      Sarepta Therapeutics stock has seen a steep share price decline over the past few years, yet on current market multiples it still screens as expensive rather than clearly cheap. With the valuation checks giving a mixed signal, investors are left weighing recent performance against the current pricing. The share price decline of around 84.7% over the past 3 years points to a company where expectations have reset sharply and long term holders have faced heavy losses. Future progress in Sarepta...

      Aug 25Yahoo FinanceSRPT

      This is the newest page. Registered accounts read further back.